AMO Pharma Initiates P-II REACH-CDM study of AMO-02 (tideglusib) to treat Congenital Myotonic Dystrophy
Shots:
- The P-II REACH-CDM evaluate the efficacy and safety of AMO-02 (tideglusib) in 56 patients to treat congenital Myotonic Dystrophy in the U.S and Canada with additional sites in Australia- New Zealand- and other countries to be added seeking local approvals
- The REACH-CDM study was designed on the basis of positive P-II data results which were recently published in the peer-reviewed journal Pediatric Neurology.
- AMO-02 is a clinical-stage investigation medicine & in development for the treatment of congenital myotonic dystrophy and has potential use in CNS- neuromuscular and other orphan indications
Ref: PRNewswire | Image: The Pharma Letter
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com